Dutogliptin, a selective DPP4 inhibitor, improves glycaemic control in patients with type 2 diabetes: a 12-week, double-blind, randomized, placebo-controlled, multicentre trial.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples